APYX MEDICAL CORP (APYX) Fundamental Analysis & Valuation

NASDAQ:APYX • US03837C1062

Current stock price

3.48 USD
-0.05 (-1.42%)
At close:
3.478 USD
0 (-0.06%)
After Hours:

This APYX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. APYX Profitability Analysis

1.1 Basic Checks

  • In the past year APYX has reported negative net income.
  • In the past year APYX has reported a negative cash flow from operations.
  • APYX had negative earnings in each of the past 5 years.
  • APYX had a negative operating cash flow in each of the past 5 years.
APYX Yearly Net Income VS EBIT VS OCF VS FCFAPYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

1.2 Ratios

  • APYX has a Return On Assets (-16.77%) which is in line with its industry peers.
  • APYX has a Return On Equity of -77.10%. This is comparable to the rest of the industry: APYX outperforms 41.30% of its industry peers.
Industry RankSector Rank
ROA -16.77%
ROE -77.1%
ROIC N/A
ROA(3y)-25.52%
ROA(5y)-28.68%
ROE(3y)-104.1%
ROE(5y)-80.45%
ROIC(3y)N/A
ROIC(5y)N/A
APYX Yearly ROA, ROE, ROICAPYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

1.3 Margins

  • APYX's Gross Margin of 62.53% is fine compared to the rest of the industry. APYX outperforms 66.30% of its industry peers.
  • In the last couple of years the Gross Margin of APYX has remained more or less at the same level.
  • APYX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5Y-0.2%
APYX Yearly Profit, Operating, Gross MarginsAPYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. APYX Health Analysis

2.1 Basic Checks

  • APYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • APYX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for APYX has been increased compared to 5 years ago.
  • Compared to 1 year ago, APYX has an improved debt to assets ratio.
APYX Yearly Shares OutstandingAPYX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
APYX Yearly Total Debt VS Total AssetsAPYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • APYX has an Altman-Z score of 1.14. This is a bad value and indicates that APYX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.14, APYX is in line with its industry, outperforming 50.54% of the companies in the same industry.
  • A Debt/Equity ratio of 2.40 is on the high side and indicates that APYX has dependencies on debt financing.
  • The Debt to Equity ratio of APYX (2.40) is worse than 83.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.4
Debt/FCF N/A
Altman-Z 1.14
ROIC/WACCN/A
WACC11.12%
APYX Yearly LT Debt VS Equity VS FCFAPYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 5.00 indicates that APYX has no problem at all paying its short term obligations.
  • APYX has a better Current ratio (5.00) than 76.09% of its industry peers.
  • APYX has a Quick Ratio of 4.26. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.
  • APYX has a Quick ratio of 4.26. This is in the better half of the industry: APYX outperforms 74.46% of its industry peers.
Industry RankSector Rank
Current Ratio 5
Quick Ratio 4.26
APYX Yearly Current Assets VS Current LiabilitesAPYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. APYX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 59.70% over the past year.
  • Looking at the last year, APYX shows a quite strong growth in Revenue. The Revenue has grown by 9.86% in the last year.
  • APYX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.78% yearly.
EPS 1Y (TTM)59.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)9.86%
Revenue growth 3Y5.89%
Revenue growth 5Y13.78%
Sales Q2Q%34.75%

3.2 Future

  • APYX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.57% yearly.
  • APYX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.71% yearly.
EPS Next Y-37.89%
EPS Next 2Y-11.65%
EPS Next 3Y23.57%
EPS Next 5YN/A
Revenue Next Year11.3%
Revenue Next 2Y10.69%
Revenue Next 3Y11.71%
Revenue Next 5Y46.71%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
APYX Yearly Revenue VS EstimatesAPYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
APYX Yearly EPS VS EstimatesAPYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. APYX Valuation Analysis

4.1 Price/Earnings Ratio

  • APYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year APYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APYX Price Earnings VS Forward Price EarningsAPYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APYX Per share dataAPYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • APYX's earnings are expected to grow with 23.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.65%
EPS Next 3Y23.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. APYX Dividend Analysis

5.1 Amount

  • APYX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APYX Fundamentals: All Metrics, Ratios and Statistics

APYX MEDICAL CORP

NASDAQ:APYX (3/20/2026, 8:00:01 PM)

After market: 3.478 0 (-0.06%)

3.48

-0.05 (-1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-10
Earnings (Next)05-06
Inst Owners44.27%
Inst Owner Change20.23%
Ins Owners13.42%
Ins Owner Change0%
Market Cap145.57M
Revenue(TTM)52.84M
Net Income(TTM)-11.21M
Analysts80
Price Target5.87 (68.68%)
Short Float %0.5%
Short Ratio1.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.4%
Min EPS beat(2)48.63%
Max EPS beat(2)52.18%
EPS beat(4)4
Avg EPS beat(4)31.14%
Min EPS beat(4)5.46%
Max EPS beat(4)52.18%
EPS beat(8)7
Avg EPS beat(8)22.81%
EPS beat(12)8
Avg EPS beat(12)7.28%
EPS beat(16)9
Avg EPS beat(16)3.63%
Revenue beat(2)2
Avg Revenue beat(2)3.65%
Min Revenue beat(2)2.11%
Max Revenue beat(2)5.19%
Revenue beat(4)2
Avg Revenue beat(4)0.27%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)5.19%
Revenue beat(8)5
Avg Revenue beat(8)1.38%
Revenue beat(12)6
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)-2.36%
PT rev (1m)0%
PT rev (3m)1.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.75
P/FCF N/A
P/OCF N/A
P/B 10.01
P/tB 10.01
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS1.26
BVpS0.35
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.77%
ROE -77.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.53%
FCFM N/A
ROA(3y)-25.52%
ROA(5y)-28.68%
ROE(3y)-104.1%
ROE(5y)-80.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5Y-0.2%
F-Score5
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 2.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 170.08%
Cap/Sales 2.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5
Quick Ratio 4.26
Altman-Z 1.14
F-Score5
WACC11.12%
ROIC/WACCN/A
Cap/Depr(3y)122.55%
Cap/Depr(5y)112.22%
Cap/Sales(3y)1.54%
Cap/Sales(5y)1.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-37.89%
EPS Next 2Y-11.65%
EPS Next 3Y23.57%
EPS Next 5YN/A
Revenue 1Y (TTM)9.86%
Revenue growth 3Y5.89%
Revenue growth 5Y13.78%
Sales Q2Q%34.75%
Revenue Next Year11.3%
Revenue Next 2Y10.69%
Revenue Next 3Y11.71%
Revenue Next 5Y46.71%
EBIT growth 1Y65.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.78%
EBIT Next 3Y57.41%
EBIT Next 5YN/A
FCF growth 1Y51.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.67%
OCF growth 3YN/A
OCF growth 5YN/A

APYX MEDICAL CORP / APYX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for APYX MEDICAL CORP?

ChartMill assigns a fundamental rating of 3 / 10 to APYX.


What is the valuation status for APYX stock?

ChartMill assigns a valuation rating of 1 / 10 to APYX MEDICAL CORP (APYX). This can be considered as Overvalued.


What is the profitability of APYX stock?

APYX MEDICAL CORP (APYX) has a profitability rating of 1 / 10.